Terms: = Bone cancer AND KMT2C, ENSG00000055609, MLL3, 58508 AND Prognosis
5 results:
1. Osteosarcoma's genetic landscape painted by genes' mutations.
Urban W; Krzystańska D; Piekarz M; Nazar J; Jankowska A
Acta Biochim Pol; 2023 Sep; 70(3):671-678. PubMed ID: 37717265
[TBL] [Abstract] [Full Text] [Related]
2. kmt2c mutation in a Chinese man with primary multidrug-resistant metastatic adenocarcinoma of rete testis: a case report.
Zhang Y; He X; Gao H
BMC Urol; 2022 Aug; 22(1):123. PubMed ID: 35945529
[TBL] [Abstract] [Full Text] [Related]
3. Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma.
Zhang L; Zhang R; Wang J; Chen Y; Qiao C; Shi Q; Jin Y; Shen X; Li J; Chen L
Clin Epigenetics; 2022 Jul; 14(1):93. PubMed ID: 35870987
[TBL] [Abstract] [Full Text] [Related]
4. A Multicentre Clinical Study of Sarcoma Personalised Treatment Using Patient-Derived Tumour Xenografts.
Xu H; Zheng H; Zhang Q; Song H; Wang Q; Xiao J; Dong Y; Shen Z; Wang S; Wu S; Wei Y; Lu W; Zhu Y; Niu X
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e48-e59. PubMed ID: 35781406
[TBL] [Abstract] [Full Text] [Related]
5. Clinical impact of kmt2c and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.
Kayser S; Feszler M; Krzykalla J; Schick M; Kramer M; Benner A; Thol F; Platzbecker U; Müller-Tidow C; Ho AD; Ehninger G; Heuser M; Schlenk RF; Thiede C; Röllig C; Krämer A
Eur J Haematol; 2017 Dec; 99(6):544-552. PubMed ID: 28940816
[TBL] [Abstract] [Full Text] [Related]
